Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63+0.00 (+0.13%)
Close on Nov 18, 2026Market cap $23.87MP/E –Yield –
Metagenomi Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Metagenomi Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$100.57M. For fiscal 2025 it was -$96.01M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$96.01M | – |
| FY2024 | Dec 31, 2024 | -$88.90M | – |
| FY2023 | Dec 31, 2023 | -$78.49M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.84M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.99M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.86M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.94M | – |
See a number that looks wrong?